If the industry intends to resist a new statutory pricing framework, which would be fair enough, it must honestly consider what that would look like in practice. Is it prepared to manage the short-term consequences? Is it able to withstand political pressure, public scrutiny, and the effects on its day-to-day dealings with the Government?
The industry is probably right to resist, it just needs to prepare for the response
December 16, 2025 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Australians turn to local pharmacies as frontline of everyday healthcare
March 13, 2026 - - Latest News -
Sandoz and Camp Quality unite to strengthen support for Australian families facing childhood cancer
March 13, 2026 - - Latest News -
The leadership challenge behind Australia’s medicine access gap
March 13, 2026 - - Latest News -
Australia has spent four decades having the wrong conversation about medicines access
March 13, 2026 - - Latest News -
‘An absolute medical miracle’ - MPs highlight progress and challenges at Cystic Fibrosis event
March 13, 2026 - - Latest News -
Australia’s top community pharmacists honoured at national awards
March 13, 2026 - - Latest News -
A new prostate cancer technology moves closer to global trials after strong early results
March 12, 2026 - - Australian Biotech

